Immunovia AB is a Swedish molecular diagnostics company that has developed what can become the world’s first robust test for early diagnosis of pancreatic cancer, which is the fourth deadliest cancer form in the world.
Out of the patients diagnosed with this type of cancer, only 3-4% survive after 5 years. The main problem is that there is no adequate technology on the market today for early detection of the cancer.
Mats Grahn, CEO at Immunovia, comments:
“Vator Securities’ performance as an advisor has been beyond expectations. The team at Vator Securities possess good industry knowledge and has shown great commitment throughout the process. Overall, it has led to a successful financing round. We are pleased to have selected Vator Securities as our financial advisor.”